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ABSTRACT 
 In present study, different transdermal patches of Pioglitazone hydrochloride were prepared using different 
polymers and evaluated on many parameters. Locally fabricated Franz diffusion cell was used for the in-vitro 
release study. Result revealed that there is a direct relationship with weight of the patch and drug content. The 
thickness lies in the range of 0.027 to 0.038mm. Average thickness was almost uniform within same 
formulation, a small variation in thickness was observed with different formulations.  The weight of patches 
lies in the range of 43.31 to 46.3 mg. The percentage of the drug content lies in the range of 96.87 to 99.28. 
Content uniformity studies proved that the amount of Pioglitazone hydrochloride in each patch of 2.009 cm
2 
was found to be fairly uniform. Percent moisture absorption was found to be in the range of 4.388 to 5.465, 
largest in formulations of batch code T3 and least in the batch code T2.The prepared transdermal drug delivery 
system of Pioglitazone hydrochloride using different polymers such as HPMC, EC, Chitosan and PVP had 
shown good promising results for all the evaluated parameters. However, for the in-vitro drug release and drug 
content result, formulation T4 was shown to be the optimized formulation, as higher percentage of drug release 
was obtained. 
Keywords: in-vitro release, Pioglitazone hydrochloride, stability studies, transdermal patches, 
TDDS. 
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INTRODUCTION 
Transdermal therapeutic systems are defined as 
‘self contained’ discrete dosage forms which, when 
applied to the intact skin, deliver the drug(s), 
through the skin, at a controlled rate to the 
systemic circulation
1
.Transdermal route is more 
convenient as compared to parenteral and oral 
routes, as it improve patient compliance (no pain) 
and avoid first pass metabolism respectively. A 
transdermal patch is a medicated adhesive patch 
that is placed above the skin to deliver a specific 
dose of drug through the skin with a predetermined 
rate of release to reach 
 
in to the systemic circulation
2
. Transdermal 
delivery provides controlled, constant 
administration of the drug; it allows continuous 
input of drugs with short biological half-lives and 
decreases the undesirable side effects, improve 
physiological and pharmacological response, avoid  
the  fluctuation  in  drug  levels,  inter  and  intra 
patient  variations
3
. 
Pioglitazone hydrochloride is a thiazolidinedione 
antidiabetic agent; it decreases insulin resistance in 
the periphery and in the liver resulting in increased 
insulin dependent glucose disposal and decreased 
hepatic glucose output
4
. It improve glucose and, in  
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part, lipid metabolism by increasing insulin 
sensitivity in insulin-sensitive tissues in diabetic 
patients. It is a potent and highly selective agonist 
for peroxisome proliferator activated receptor 
gamma (PPARγ) that are  present in tissues such as 
adipose tissue, skeletal muscle,  and liver. 
Activation of PPARγ nuclear receptors modulates 
the transcription of a  number of insulin responsive 
genes involved in the control of glucose and lipid  
metabolism
5
.Pioglitazone hydrochloride was 
selected as a candidate for the development of 
transdermal patches as it has a short half-life, is 
extensively metabolized by  hydroxylation and 
oxidation and requires one to two times daily 
dosing. Also unfluctuating plasma  concentrations 
for effective management of blood sugar for long 
periods in  diabetic patients can be maintained by 
transdermal patches
6
.  
MATERIALS AND METHODS 
 Pioglitazone hydrochloride and HPMC K100 was 
received as gift sample from Afrik 
Pharmaceuticals Limited, Ethyl cellulose, and 
Chitosan from Dana Drugs Limited, Nigeria.   
Fabrication of the drug free films 
A fixed volume of polymer solution with 
plasticizer was poured onto a glass petri dish. The 
Petri dish was placed on an even and smooth 
surface to ensure uniform spreading of the polymer 
solution. After it, solution was then placed in an 
oven. An inverted funnel was placed on the petri 
dish to facilitate the evaporation of the solvent at 
the controlled rate over the drying periods of 12 
hrs at 40 C. The film thus formed was retrieved 
by cutting along the edges with a sharp razor 
blade
7
. 
 
 
 
 
 
Fabrication of the Pioglitazone hydrochloride 
loaded polymeric films  
The drug loaded polymeric films were prepared in  
a similar manner as mentioned above except that a 
weighed quantity of the 200mg Pioglitazone 
hydrochloride was added to the polymer solution 
containing the plasticizer. This solution was 
poured into a glass petri dish. An inverted funnel 
was placed on it to control the rate of evaporation. 
The whole assembly was maintained at 40C in hot 
air oven
8
. After 12hrs the film was lifted from the 
surface of petridish after the cutting the edges with 
a sharp razor. The film thus formed was 
neutralized with 2%  NaOH and dried.  
EVALUATION OF  TRANSDERMAL 
PATCHES 
1. Thickness  
The thickness of each film was measured at five 
different places by means of a screw gauge
9
.  
2. Weight Uniformity 
Five patches (area=2.009 cm
2
) of each film were 
weighed accurately and the average weight of the 
patch was found out
10
.  
3. Content Uniformity 
To determine the amount of Pioglitazone 
hydrochloride in the patches, the patch of 2.009 
cm
2
 area was dissolved in 10ml of phosphate 
buffer solution (pH 7.4) and then after dilution the 
amount was measured spectrophotometrically at 
269 nm
11
.  
4. Folding Endurance 
The folding endurance of the patch was determined 
by repeatedly folding one patch at the same place 
up to 290 times, which was considered satisfactory 
to reveal good patch properties
12
. The number of 
times the patch could be folded at the same place  
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without breaking gave the value of folding 
endurance.  
5.  Percentage moisture loss
 
  
The films were weighted accurately and kept in a 
desiccators containing anhydrous calcium chloride. 
After 3 days, the films were taken out and 
weighed
13
.  
6. Percentage  moisture content  
The prepared films were weighed individually and 
kept in a dessicator containing silica at room 
temperature and the films were weighed again and 
again until they showed a constant weight. The 
percentage moisture content was calculated using 
the following formula
14
.  
 
7. Percentage moisture absorption 
The films were weighed accurately and placed in 
the desiccator containing 100 ml of saturated 
solution of aluminum chloride which maintains 
79.50% RH. After 3 days the films were taken out 
and weighed. The percentage moisture absorption 
was calculated using the formula
15
.  
 
8. Water vapour transmission rate 
For this study vials of equal diameter were used as 
transmission cells. These cells were washed 
thoroughly an dried in an oven. About 1.0 g of 
fused calcium chloride was taken in the cells and 
the polymeric films measuring 2.009cm
2
 area were 
fixed over the brim with the help of an  
 
 
 
 
 
 
 
Adhesive
16
. The cells were weighed accurately and 
initial weight is recorded and then kept in a closed 
desiccator containing saturated solution of 
potassium chloride (200ml), containing humidity 
between 80-90% RH. The cells were taken out and 
weighed after 1, 2, 3, 4, 5, 6, and 7
th
 day of 
storage. From increase in the weights the amount 
of water vapour transmitted and rate at which 
water vapour transmitted were calculated as shown 
below. 
WVTR =
Final Weight –  Initial Weight 
 Time x Area  
X100 
9. Flatness  
Longitudinal  strips of 1.6 cm in  length were cut 
out from the prepared medicated film and than 
variation in the lengths due to the non-uniformity 
in flatness was measured
17
. 
Flatness was calculated by measuring constriction 
of strips and a zero percent constriction was 
considered to be equal to a hundred percent 
flatness. 
Constriction (%)   =
l1 –  l2 
  l2 
X100 
Where, l1 = final length of each strip, and   l2 = 
initial length  
10.  In-vitro release studies   
A modified Franz-diffusion cell which is also 
called Keshary–Chein cell was fabricated to study 
the in-vitro release profile. Donor compartment of 
it was exposed to ambient temperature and a 
receptor compartment, which was maintained at 
37
0
C. The patches were stuck to an aluminum foil 
which was previously cut to have a diameter of 2 
cm and a slightly larger patch was fixed using an 
water-impermeable adhesive
18
. 
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The mouth of the cell was coated with a thin layer 
of silicone grease to prevent leakage of the 
receptor fluid 1ml of the receptor fluid was 
withdrawn at periodic interval for 10 hrs. It was 
immediately replaced with 1 ml of fresh drug free 
buffer (pH 7.4) solution to maintain constant 
volume. The fluid removed, after suitable dilution 
with phosphate buffer was analyzed 
spectrophotometrically at 269 nm. 
RESULTS AND DISCUSSION 
 Four transdermal patches formulations of 
Pioglitazone hydrochloride were prepared by using 
different polymers i.e. HPMC, chitosan, PVP K30, 
EC, in different ratio.   
Thickness lies in the range of 0.027 to 0.038 mm. 
Average thickness was almost uniform within 
same formulation a small variation in thickness 
was observed with different formulations. The 
variations in thickness may be due to viscosity of 
polymer solutions of different formulations. The 
other reasons may be due to lack of temperature 
control which have affected the controlled 
evaporation of solvent from the wet film surface. 
There is a direct relationship with weight of the 
patch and drug content. The weight of patches lies 
in the range of 43.31 to 46.3 mg. The percentage 
drug content lies in the range of 96.87 to 99.28. 
Content uniformity studies proved that the amount 
of Pioglitazone hydrochloride in each patch of 
2.009 cm
2
 was found to be fairly uniform. Percent 
moisture absorption was found to be in the range 
of 4.388 to 5.465, largest in formulations of batch 
code T3 and least in the batch code T2.   
 
  
 
 
 
 
 
Percent moisture content was found to be in the 
range of 2.56 to 3.21. 
The folding endurance was measured manually; 
films were folded 290 times and if the films show 
any cracks it was taken as the end point. The 
folding endurance represents the elasticity of the 
patches. 
The in-vitro permeation of Pioglitazone 
hydrochloride transdermal patches formulation 
was studied using locally fabricated Franz 
diffusion cell. The cumulative percent drug release 
after 12 hrs in between 51.4 to 82.11. Largest in 
batch code T4 and least in formulations of batch 
code T3. Rapid drug leakage was observed during 
the initial phase. However, after that a slow release 
occurred. It was also observed that the drug release 
generally decreased as the polymer ratio increased. 
The release of the drug was retarded due to the 
hydrophobic and insoluble nature of the polymers 
used. These results indicate hydrophilic nature of 
polymer PVP K30. Hydrophobic polymer has less 
affinity for water, this results in decrease in 
thermodynamic activity of the drug in the film and 
decreased drug release. The drug release was 
found to increase on increasing the concentration 
of hydrophilic polymer in the polymer matrix. This 
is due to the facts that dissolution of the aqueous 
soluble fraction of the polymer matrix leads to the 
formation of gelaneous   pores. The formation of 
such pores leads to a decrease in the mean 
diffusional path length of the drug molecules to 
release into the diffusion medium and hence to 
higher release rates. 
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CONCLUSION  
The prepared transdermal drug delivery system of 
Pioglitazone hydrochloride using different 
polymers such as HPMC, EC, Chitosan and PVP  
had shown good promising result for all the 
evaluated parameters. Based on the in-vitro drug 
release and drug content, formulation T4 was 
concluded as an optimized formulation, which 
shows its higher percentage of drug release. 
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Table 1: Compositions of the Pioglitazone hydrochloride transdermal patches 
Batch Polymer ratio Solvent Plasticizer 
(20%) 
T1 Chitosan :Ethyl 
cellulose:: 20:80   
Acetic acid (1 
% w/v)  
Castor oil  
T2 Chitosan :Ethyl 
cellulose:: 80:20   
Acetic acid (1 
% w/v) 
Castor oil  
T3 HPMC:PVP 
K30::20:80 
Dichloromethan
e (2% w/v) 
Glycerine  
T4 HPMC:PVP 
K30::20:80 
Dichloromethan
e (2% w/v) 
Glycerine  
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Table 2:  Physical Characterization of transdermal patches 
Parameter T1 T2 T3 T4 
Physical Appearance 
Smooth 
flexible but 
wrinkled 
Smooth tough Hard and tough Smooth tough 
 
Thickness (mm)  SD 0.028±0.32 0.031±0.25 0.027±0.58 0.038±0.02 
Mass uniformity (mg) 
46.3±0.35 
45.7±0.51 44.3±0.16 
43.31±0.23 
% Drug content 99.28±0.34 98.66±0.34 97.42±0.12 96.87± 0.42 
% Moisture Content 
3.21±0.25 
2.56 ±0.26 2.78 ±0.25 2.88±0.25 
% Moisture absorption 5.342±0.46 4.388±0.82 5.465 ±0.58 4.521±0.33 
% Moisture loss    3.763±0.14 
3.573±0.15 
3.146 ±0.24 3.485±0.32 
WVTR (g/cm
2
/hrs 1.521X10
-4
± 0.12 
1.489 X10
-4
± 0.27 
1.543X10
-4
±0.08 1.443X10
-4
± 0.12 
Folding endurance > 278 > 285 > 262 > 270 
Flatness 
100% 100% 100% 100% 
 
 
 
Figure 1: % drug released from Pioglitazone hydrochloride transdermal patches 
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